<DOC>
	<DOCNO>NCT00461552</DOCNO>
	<brief_summary>To determine efficacy safety 4 therapeutic intervention HAART-Induced lipodystrophy . The intervention : 1 ) Dietary - effect high carbohydrate vs.a high cis-monounsaturated fatty acid diet . 2 ) The effect aerobic exercise dietary advice . 3 ) The effect Omega-3 Fish Oil Capsules . 4 ) The effect leptin therapy . These intervention aim improve metabolic complication HAART therapy elevate lipid , insulin resistance diabetes .</brief_summary>
	<brief_title>Therapeutic Approaches HAART-Induced Lipodystrophy</brief_title>
	<detailed_description>Patients HAART-induced lipodystrophy report loss subcutaneous ( sc ) fat extremity face excess fat accumulation neck truncal region . They also predispose metabolic complication insulin resistance , , dyslipidemia diabetes mellitus . The pathogenesis HAART-induced lipodystrophy fully understood although PIs strongly implicate cause . The metabolic complication pose increase risk atherosclerosis acute pancreatitis whereas change body fat distribution cause physical discomfort psychological distress . Management problem pose therapeutic challenge . We propose potentially safe therapeutic lifestyle change well novel therapy management HAART-induced lipodystrophy metabolic complication . The hypothesis test aim : Hypothesis 1 : A diet rich cis-monounsaturated fatty acid improve HAART-induced glucose intolerance dyslipidemia HIV-infected patient . Aim 1 : To compare acceptability effect isocaloric diet rich carbohydrates cis-monounsaturated fat , give 6 wk , glucose lipid metabolism patient HAART-induced dyslipidemia randomize , cross-over study . Hypothesis 2 : A regimen aerobic exercise improve insulin resistance , dyslipidemia body fat distribution HIV-infected patient HAART-induced lipodystrophy . Aim 2 : To determine effect supervise aerobic exercise regimen dietary advice glucose lipid metabolism , body fat distribution HIV-infected patient HAART-induced lipodystrophy . Hypothesis 3 : The n-3 polyunsaturated fat improve HAART-induced dyslipidemia HIV-infected patient . Aim 3 : To determine lipid-lowering effect n-3 polyunsaturated fat randomize , double-blind , placebo-controlled , crossover trial HIV-infected patient HAART-induced dyslipidemia . Hypothesis 4 : Leptin replacement improve insulin resistance , dyslipidemia body fat distribution patient HAART-induced lipodystrophy hypoleptinemia . Aim 4 To study efficacy safety recombinant methionyl leptin ( r-metHuleptin ) improve insulin sensitivity , dyslipidemia body fat distribution patient HAART-induced lipodystrophy hypoleptinemia use randomize , double-blind , placebo-controlled , parallel design . Results study may help design therapeutic approach HAART-induced lipodystrophy metabolic complication well prevention problem HIV-infected patient place HAART .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<criteria>Inclusion Criteria General inclusion : Age &gt; 14 year HIV infection treat HIV1 protease inhibitor &gt; 6 month currently , previous protease inhibitor therapy least 2 year duration development lipodystrophy current stable therapy preferably past 4 month . Fasting serum triglyceride &gt; 200 mg/dL Exclusion Criteria General exclusion : Acute , ongoing AIDSdefining opportunistic infection . Blood CD4 positive lymphocyte count &lt; 200/mm3 Known liver disease due cause nonalcoholic steatohepatitis elevation liver transaminases two half time upper limit normal ( SGOT &gt; 105 U/L , SGPT &gt; 120 U/L ) total bilirubin ( &gt; 1.5 mg/dL ) . Hematocrit le 30 % . Current alcohol abuse ( &gt; 7 drink 210 g per wk woman &gt; 14 drink 420 g per wk men ) . Current substance abuse . Uncontrolled diabetes mellitus fast plasma glucose &gt; 180 mg/dL hemoglobin A1c &gt; 9 % . History weight loss last 3 month . Use anorexiogenic drug , thiazolidinediones , anabolic steroid human growth hormone . Major Neuropsychiatric illness impede competence compliance . Pregnant lactating woman . Cancer exclude skin cancer melanoma . Acute medical illness preclude participation study . Chronic renal insufficiency serum creatinine &gt; 2 mg/dL . Untreated thyroid disorder hypothyroidism hyperthyroidism . Each 4 treatment arm additional specific inclusion exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Lipodystrophy</keyword>
	<keyword>HIV</keyword>
	<keyword>HAART</keyword>
	<keyword>HIV Lipodystrophy Syndrome</keyword>
	<keyword>Lipodystrophy syndrome</keyword>
	<keyword>HIV-Associated Lipodystrophy</keyword>
	<keyword>HIV-Associated Lipodystrophy Syndrome</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>